688176 亚虹医药
已收盘 05-17 15:00:00
资讯
新帖
简况
亚虹医药(688176.SH)：APL-1702(盐酸氨酮戊酸己酯软膏光动力治疗系统)上市申请获受理
智通财经 · 05-12
亚虹医药(688176.SH)：APL-1702(盐酸氨酮戊酸己酯软膏光动力治疗系统)上市申请获受理
亚虹医药：累计回购约357万股
每日经济新闻 · 05-06
亚虹医药：累计回购约357万股
亚虹医药(688176.SH)：已累计回购0.6266%股份
格隆汇资讯 · 05-06
亚虹医药(688176.SH)：已累计回购0.6266%股份
【风口解读】两款引进产品持续放量，亚虹医药一季度营收环比大增126.08%
泡财经 · 04-29
【风口解读】两款引进产品持续放量，亚虹医药一季度营收环比大增126.08%
亚虹医药：2024年第一季度净利润约-8285万元
每日经济新闻 · 04-29
亚虹医药：2024年第一季度净利润约-8285万元
亚虹医药(688176.SH)一季度营收环比增长126%
格隆汇资讯 · 04-29
亚虹医药(688176.SH)一季度营收环比增长126%
亚虹医药：奥博资本投资者于4月23日调研我司
证券之星 · 04-24
亚虹医药：奥博资本投资者于4月23日调研我司
4月23日亚虹医药-U涨7.62%，华安宏利混合A基金重仓该股
证券之星 · 04-23
4月23日亚虹医药-U涨7.62%，华安宏利混合A基金重仓该股
亚虹医药-U涨7.62%，太平洋二个月前给出“买入”评级，目标价13.70元
证券之星 · 04-23
亚虹医药-U涨7.62%，太平洋二个月前给出“买入”评级，目标价13.70元
亚虹医药-U大幅上涨 近半年3家券商买入
智选洞察 · 04-23
亚虹医药-U大幅上涨 近半年3家券商买入
【机构调研记录】中海基金调研晶晨股份、亚虹医药等4只个股（附名单）
证券之星 · 04-23
【机构调研记录】中海基金调研晶晨股份、亚虹医药等4只个股（附名单）
亚虹医药：4月19日高管PAN KE增持股份合计15.5万股
证券之星 · 04-22
亚虹医药：4月19日高管PAN KE增持股份合计15.5万股
亚虹医药(688176)：APL-1702NDA在即 期待商业化放量
西南证券股份有... · 04-22
亚虹医药(688176)：APL-1702NDA在即 期待商业化放量
亚虹医药： APL-1706的上市申请已于2023年11月获国家药品监督管理局受理
证券之星 · 04-22
亚虹医药： APL-1706的上市申请已于2023年11月获国家药品监督管理局受理
亚虹医药：4月19日召开业绩说明会，中邮创业基金、翼虎投资等多家机构参与
证券之星 · 04-22
亚虹医药：4月19日召开业绩说明会，中邮创业基金、翼虎投资等多家机构参与
亚虹医药：控股股东及高级管理人员等增持主体已达到并超过本次增持计划拟增持金额区间下限的50%，本次增持股份计划尚未实施完毕
金融界 · 04-19
亚虹医药：控股股东及高级管理人员等增持主体已达到并超过本次增持计划拟增持金额区间下限的50%，本次增持股份计划尚未实施完毕
亚虹医药2023年净亏4亿元 核心产品均属于在研状态
经济参考网 · 04-18
亚虹医药2023年净亏4亿元 核心产品均属于在研状态
亚虹医药：专科化战略取得显著成果 多个产品临床开发取得重要进展
财通社 · 04-18
亚虹医药：专科化战略取得显著成果 多个产品临床开发取得重要进展
图解亚虹医药年报：第四季度单季净利润同比减58.11%
证券之星 · 04-18
图解亚虹医药年报：第四季度单季净利润同比减58.11%
亚虹医药：2023年度净利润约-4亿元
每日经济新闻 · 04-17
亚虹医药：2023年度净利润约-4亿元
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域创新药的研发、生产和销售。公司的主要产品是APL-1702、APL-1202、APL-1501(第二代APL-1202)、APL-1706、APLD-2304、AT-014、AT-020、APL-2302、AT-017、AT-018、AT-021、APL-1401、APL-2301。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":6.38,"timestamp":1715929200000,"preClose":6.28,"halted":0,"volume":5639147,"delay":0,"floatShares":371000000,"shares":570000000,"eps":-0.7375,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"05-17 15:00:00","open":6.28,"high":6.4,"low":6.22,"amount":35540400,"amplitude":0.0287,"askPrice":6.39,"askSize":986,"bidPrice":6.38,"bidSize":301,"shortable":0,"etf":0,"ttmEps":-0.7375,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":6.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":6.91,"lowLimit":5.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":570000000,"pbRate":1.58,"roa":"--","roe":"--","epsLYR":-0.7,"committee":-0.215322,"marketValue":3637000000,"floatMarketCap":2370000000,"peRate":-8.650847,"changeRate":0.0159,"turnoverRate":0.0152,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-20。","afterMarket":{"amount":0,"volume":0,"close":6.38,"buyVolume":0,"sellVolume":0,"time":1715931239505,"indexStatus":"已收盘 05-17 15:30:00","preClose":6.28}},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2434380618","title":"亚虹医药(688176.SH)：APL-1702(盐酸氨酮戊酸己酯软膏光动力治疗系统)上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2434380618","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434380618?lang=zh_cn&edition=full","pubTime":"2024-05-12 15:52","pubTimestamp":1715500350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，公司近日收到国家药品监督管理局(NMPA)核准签发的《受理通知书》，公司产品APL-1702(通用名：盐酸氨酮戊酸己酯软膏光动力治疗系统)拟用于治疗18岁及以上排除原位癌的经组织学证实的宫颈高级别鳞状上皮内病变(High-Grade Squamous Intraepithelial Lesion, HSIL)患者的上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120197.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433507444","title":"亚虹医药：累计回购约357万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433507444","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2433507444?lang=zh_cn&edition=full","pubTime":"2024-05-06 17:09","pubTimestamp":1714986586,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚虹医药 5月6日晚间发布公告称，截至2024年4月30日，公司已累计回购股份约357万股，占公司总股本的比例为0.6266%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.33元/股，支付的资金总额为人民币2298.33万元不含印花税、交易佣金等交易费用）。2023年1至12月份，亚虹医药的营业收入构成为：医药制造业占比100.0%。截至发稿，亚虹医药市值为38亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061728358b796041&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061728358b796041&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433386446","title":"亚虹医药(688176.SH)：已累计回购0.6266%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2433386446","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2433386446?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:54","pubTimestamp":1714985647,"startTime":"0","endTime":"0","summary":"格隆汇5月6日丨亚虹医药(688176.SH)公布，截至2024年4月30日，公司已累计回购股份3,571,534股，占公司总股本的比例为0.6266%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.33元/股，支付的资金总额为人民币2,298.33万元（不含印花税、交易佣金等交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050616542087d7d7a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050616542087d7d7a1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431886377","title":"【风口解读】两款引进产品持续放量，亚虹医药一季度营收环比大增126.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431886377","media":"泡财经","top":-1,"share":"https://www.laohu8.com/m/news/2431886377?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:19","pubTimestamp":1714396743,"startTime":"0","endTime":"0","summary":"泡财经获悉，4月29日晚间，亚虹医药发布2024年第一季度报告，实现营收2431.95万元，环比增长126.08%。今年一季度，两款产品销售放量。亚虹医药是一家专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化专科创新药公司。2024年以来，亚虹医药研发成果加速转化，多款核心产品有望迎来收获期。该产品的上市申请已于2023年11月获得国家药监局受理，公司正在积极推进其上市审评审批工作，并期望于2025年6月底前获得上市批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292119438b624528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292119438b624528&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431427877","title":"亚虹医药：2024年第一季度净利润约-8285万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431427877","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431427877?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:17","pubTimestamp":1714396632,"startTime":"0","endTime":"0","summary":"亚虹医药（SH 688176，收盘价：6.67元）4月29日晚间发布一季度业绩公告称，2024年第一季度营收约2432万元，同比增加106217.71%；归属于上市公司股东的净利润亏损约8285万元；基本每股收益亏损0.15元。截至发稿，亚虹医药市值为38亿元。文章来源：每日经济新闻原标题：亚虹医药：2024年第一季度净利润约-8285万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300800558b63e8d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300800558b63e8d1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431836555","title":"亚虹医药(688176.SH)一季度营收环比增长126%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431836555","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431836555?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:30","pubTimestamp":1714386656,"startTime":"0","endTime":"0","summary":"4月29日，亚虹医药(股票代码：688176.SH)发布2024年第一季度报告，公司第一季度实现营收2431.95万元，环比增长126.08%，主要系报告期内公司销售商业化产品培唑帕尼片(商品名：迪派特)和马来酸奈拉替尼片(商品名：欧优比)产生收入。迪派特、欧优比分别于2023年10月、12月上市并开始销售，今年一季度产品销售放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918310287bed3ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918310287bed3ab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430150425","title":"亚虹医药：奥博资本投资者于4月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2430150425","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430150425?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:03","pubTimestamp":1713949432,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月24日亚虹医药发布公告称奥博资本于2024年4月23日调研我司。答：公司正在积极与监管部门开展上市申请前沟通交流咨询事宜，预计将于2024年二季度递交新药上市申请并获得受理。分别于2023年10月及2023年12月上市并开始销售，至2023年末即取得了近千万元销售额的成绩。亚虹医药主营业务：专注于泌尿生殖系统肿瘤及其它重大疾病领域,致力于为患者提供诊疗一体化解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417091387aa2370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417091387aa2370&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150762","title":"4月23日亚虹医药-U涨7.62%，华安宏利混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150762","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429150762?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:26","pubTimestamp":1713860787,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日亚虹医药-U涨7.62%，收盘报6.07元，换手率3.17%，成交量11.79万手，成交额6981.09万元。重仓亚虹医药-U的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家；过去90天内机构目标均价为13.7。根据2023基金年报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为华安宏利混合A。该公募基金现任基金经理为王春。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029717.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429415075","title":"亚虹医药-U涨7.62%，太平洋二个月前给出“买入”评级，目标价13.70元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429415075","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429415075?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:26","pubTimestamp":1713860780,"startTime":"0","endTime":"0","summary":"今日亚虹医药-U涨7.62%，收盘报6.07元。2024年2月5日，太平洋研究员周豫,霍亮发布了对亚虹医药的研报《ACCRUE研究未达主要终点，APL-1702预计24Q2提交NDA》，该研报对亚虹医药给出“买入”评级，认为其目标价为13.7元，现价距离目标价尚有125.70%的涨幅空间。假定WACC为12%，永续增长率1%，我们使用DCF法进行估值，测算出目标市值为78.10亿元人民币，对应股价为13.70元。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029712.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429306651","title":"亚虹医药-U大幅上涨 近半年3家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2429306651","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2429306651?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:13","pubTimestamp":1713849199,"startTime":"0","endTime":"0","summary":"04月23日，亚虹医药-U股价大幅上涨，截至13点13分，亚虹医药-U上涨5.14%，报5.93元/股，成交3395万元，换手率1.58%。此外，数据统计显示，近半年内3家券商给予买入建议。北向资金方面，亚虹医药-U04月22日获得北向资金增持68.25万股，截至04月22日，北向资金当前共持有亚虹医药-U594.85万股，市值3527万元，持股占流通股比为1.60%。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320537a54bf28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320537a54bf28&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429856711","title":"【机构调研记录】中海基金调研晶晨股份、亚虹医药等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2429856711","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429856711?lang=zh_cn&edition=full","pubTime":"2024-04-23 08:01","pubTimestamp":1713830476,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月22日披露的机构调研信息，中海基金近期对4家上市公司进行了调研，相关名单如下：1）晶晨股份 个股亮点：公司主营业务为多媒体智能终端SoC芯片的研发、设计与销售，芯片产品主要应用于智能机顶盒、智能电视和AI音视频系统终端等科技前沿领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300011447.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429940458","title":"亚虹医药：4月19日高管PAN KE增持股份合计15.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429940458","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429940458?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:01","pubTimestamp":1713787267,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月22日市场公开信息、上市公司公告及交易所披露数据整理，亚虹医药最新董监高及相关人员股份变动情况：2024年4月19日公司董事,高级管理人员,核心技术人员PAN KE共增持公司股份15.5万股，占公司总股本为0.0272%。亚虹医药近半年内的董监高及核心技术人员增减持详情如下：亚虹医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入292.72万，融资余额增加；融券净流入3300.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200025522.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429946621","title":"亚虹医药(688176)：APL-1702NDA在即 期待商业化放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429946621","media":"西南证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2429946621?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:21","pubTimestamp":1713781288,"startTime":"0","endTime":"0","summary":"APL-1702Ⅲ期临床达到主要研究终点，NDA在即。公司正在积极准备向国家药品监督管理局药品审评中心递交 APL-1702 的上市申请，并积极准备与美国FDA 讨论在美国市场上市的Ⅲ期临床方案。APL-1202 联合替雷利珠单抗新辅助治疗MIBC 取得积极的有效性信号。APL-1202 联合替雷利珠单抗预计将于2024 年第三季度读出Ⅱ期试验的顶线数据。同时，公司计划在中国晚期膀胱癌人群中开展APL-1202 联合免疫检查点抑制剂的临床研究。加强泌尿生殖领域产品协同，成立妇女健康事业部推动APL-1702 的营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221821328b45bfb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221821328b45bfb4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429294517","title":"亚虹医药：\nAPL-1706的上市申请已于2023年11月获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2429294517","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429294517?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:01","pubTimestamp":1713780095,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药04月22日在投资者关系平台上答复投资者关心的问题。APL-1706的上市申请已于2023年11月获国家药品监督管理局受理。公司正在积极推进其上市审评审批工作，期望于2025年6月底前获得上市批准，关于该产品的后续进展，公司将严格按照《上海证券交易所科创板股票上市规则》等相关规定履行信息披露义务。公司董监高以及持股5%以上的股东不存在以转融通渠道出售或出借股份的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200021425.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429912410","title":"亚虹医药：4月19日召开业绩说明会，中邮创业基金、翼虎投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2429912410","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429912410?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:38","pubTimestamp":1713775087,"startTime":"0","endTime":"0","summary":"PL-1706未来会参考产品自身的创新性和药物经济学评价、患者支付能力等多方面因素进行定价。分别于2023年10月及2023年12月上市并开始销售，至报告期末即取得了近千万元销售额的成绩。销售收入的快速增长，销售额过亿并实现整个事业部内部盈亏平衡，以打造公司在同行业中领先的商业化能力和运营效能。该股最近90天内共有1家机构给出评级，买入评级1家；过去90天内机构目标均价为13.7。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200017027.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428567436","title":"亚虹医药：控股股东及高级管理人员等增持主体已达到并超过本次增持计划拟增持金额区间下限的50%，本次增持股份计划尚未实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2428567436","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428567436?lang=zh_cn&edition=full","pubTime":"2024-04-19 20:24","pubTimestamp":1713529497,"startTime":"0","endTime":"0","summary":"亚虹医药 公告，公司控股股东、实际控制人、董事长兼总经理PAN KE先生，董事、董事会秘书兼财务负责人杨明远先生自2024年2月5日起6个月内，通过上海证券交易所系统允许的方式增持公司股份，合计增持金额不低于人民币400万元且不超过人民币800万元。2024年2月5日至2024年4月19日期间，增持主体通过上海证券交易所以集中竞价交易方式累计增持公司股份65.67万股，占公司总股本的0.1152%，增持金额合计人民币390.45万元。截至目前，增持主体已达到并超过本次增持计划拟增持金额区间下限的50%，本次增持股份计划尚未实施完毕，增持主体将继续实施本次增持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192029588795bd4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192029588795bd4e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428579245","title":"亚虹医药2023年净亏4亿元 核心产品均属于在研状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2428579245","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2428579245?lang=zh_cn&edition=full","pubTime":"2024-04-18 17:02","pubTimestamp":1713430920,"startTime":"0","endTime":"0","summary":"亚虹医药4月17日晚间披露了2023年年报。公开资料显示，亚虹医药成立于2010年3月16日，于2022年1月7日登陆科创板，是专注于泌尿生殖系统肿瘤及其它重大疾病领域的创新药公司。年报显示，2023年亚虹医药研发费用为3.65亿元，同比增长49.49%。公司核心产品均属于在研状态，营业收入主要系迪派特和欧优比在2023年第四季度开始商业化并产生销售收入及新增对外授权数据产生的许可费收入等，商业化产品未实现大规模销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418170513878f7078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418170513878f7078&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428587146","title":"亚虹医药：专科化战略取得显著成果 多个产品临床开发取得重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2428587146","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2428587146?lang=zh_cn&edition=full","pubTime":"2024-04-18 11:47","pubTimestamp":1713412020,"startTime":"0","endTime":"0","summary":"4月18日讯，4月17日晚，亚虹医药发布2023年年报。公告显示，公司专科化战略取得显著成果，在研产品管线取得重要进展。2023年，公司研发投入金额约3.65亿元，同比增长49.49%。截至目前，公司主要拥有13个产品、16个在研项目。同时，报告期末，公司货币资金与交易性金融资产约23.33亿元，资金储备充足，为公司稳健发展提供了保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418114809878d79f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418114809878d79f7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428329227","title":"图解亚虹医药年报：第四季度单季净利润同比减58.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428329227","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428329227?lang=zh_cn&edition=full","pubTime":"2024-04-18 00:37","pubTimestamp":1713371865,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药2023年年报显示，公司主营收入1375.33万元，同比上升52604.25%；归母净利润-4.0亿元，同比下降62.42%；扣非净利润-4.32亿元，同比下降39.41%；其中2023年第四季度，公司单季度主营收入1075.73万元，同比上升117468.9%；单季度归母净利润-1.32亿元，同比下降58.11%；单季度扣非净利润-1.38亿元，同比下降37.1%；负债率9.21%，投资收益580.74万元，财务费用-3823.74万元，毛利率79.0%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418004452878b041a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418004452878b041a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428922344","title":"亚虹医药：2023年度净利润约-4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428922344","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428922344?lang=zh_cn&edition=full","pubTime":"2024-04-17 22:03","pubTimestamp":1713362600,"startTime":"0","endTime":"0","summary":"亚虹医药（SH 688176，收盘价：5.83元）4月17日晚间发布年度业绩报告称，2023年营业收入约1375万元，同比增加52604.25%；归属于上市公司股东的净利润亏损约4亿元；基本每股收益亏损0.7元。2022年同期营业收入约2.61万元；归属于上市公司股东的净利润亏损约2.47亿元；基本每股收益亏损0.43元。2023年1至12月份，亚虹医药的营业收入构成为：医药制造业占比100.0%。截至发稿，亚虹医药市值为33亿元。文章来源：每日经济新闻原标题：亚虹医药：2023年度净利润约-4亿元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417222955878a858d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417222955878a858d&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","stockEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":0.0943},{"period":"3month","weight":0.16},{"period":"6month","weight":-0.4524},{"period":"1year","weight":-0.5689},{"period":"ytd","weight":-0.4082}],"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","perCapita":"12412股","boardName":"医药制造业","registeredCapital":"57000万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域创新药的研发、生产和销售。公司的主要产品是APL-1702、APL-1202、APL-1501(第二代APL-1202)、APL-1706、APLD-2304、AT-014、AT-020、APL-2302、AT-017、AT-018、AT-021、APL-1401、APL-2301。","serverTime":1716028230279,"listedPrice":22.98,"stockholders":"29929人(较上一季度增加2.11%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}